These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 1988103)
1. Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines. Danhauser-Riedl S; Felix SB; Houlihan WJ; Zafferani M; Steinhauser G; Oberberg D; Kalvelage H; Busch R; Rastetter J; Berdel WE Cancer Res; 1991 Jan; 51(1):43-8. PubMed ID: 1988103 [TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro. Berdel WE; Korth R; Reichert A; Houlihan WJ; Bicker U; Nomura H; Vogler WR; Benveniste J; Rastetter J Anticancer Res; 1987; 7(6):1181-7. PubMed ID: 3442414 [TBL] [Abstract][Full Text] [Related]
3. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412. Handley DA; Van Valen RG; Melden MK; Houlihan WJ; Saunders RN J Pharmacol Exp Ther; 1988 Nov; 247(2):617-23. PubMed ID: 3183958 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of hexadecylphosphocholine in neoplastic cell lines including drug-resistant sublines in vitro. Danhauser-Riedl S; Himmelmann A; Steinhauser G; Busch R; Vogler WR; Rastetter J; Berdel WE J Lipid Mediat; 1990; 2(5):271-80. PubMed ID: 2133272 [TBL] [Abstract][Full Text] [Related]
5. In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Brunton VG; Workman P Br J Cancer; 1993 May; 67(5):989-95. PubMed ID: 8388233 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914 [TBL] [Abstract][Full Text] [Related]
7. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188 [TBL] [Abstract][Full Text] [Related]
8. Lack of therapeutic effects of platelet activating factor antagonists in WEHI-3B leukemia, human xenotransplanted colorectal and lung cancer and Lewis-lung tumor in vivo. Koenigsmann M; Zafferani M; Danhauser-Riedl S; Reufi B; Houlihan WJ; Thiel E; Berdel WE Cancer Lett; 1992 Dec; 67(2-3):145-56. PubMed ID: 1483263 [TBL] [Abstract][Full Text] [Related]
9. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets. Tahraoui L; Floch A; Cavero I J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995 [TBL] [Abstract][Full Text] [Related]
10. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxic interactions of heat and an ether lipid analogue in human ovarian carcinoma cells. Fujiwara K; Modest EJ; Welander CE; Wallen CA Cancer Res; 1989 Nov; 49(22):6285-9. PubMed ID: 2804975 [TBL] [Abstract][Full Text] [Related]
12. Antiproliferative action of isatine-beta-thiocarbohydrazone and N-ethylisatine-beta-thiocarbohydrazone on human PBMC and on two neoplastic cell lines. Juranić Z; Anastasova F; Juranić I; Stanojković T; Radulović S; Vuletić N J Exp Clin Cancer Res; 1999 Sep; 18(3):317-24. PubMed ID: 10606176 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. Casals-Stenzel J; Muacevic G; Weber KH J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913 [TBL] [Abstract][Full Text] [Related]
14. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation. Tahraoui L; Floch A; Mondot S; Cavero I Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653 [TBL] [Abstract][Full Text] [Related]